Here’s what you should know:
1. The deal has been met with disapproval from several shareholders. Now an unidentified top-10 investor raised concerns over the potential value the resulting combined company would have.
2. Another group of investors formed a group called “Thinking About Takeda’s Future” to raise concerns about the deal.
3. Takeda shareholders previously voted down a proposal that would have required the company to get shareholder approval for any deal with more than $8.9 billion.
4. Takeda is completing the regulatory approval process before putting the acquisition to a formal shareholder vote.
More articles on supply chain:
4 things to know about Larry Taylor, Practice Partners in Healthcare’s CEO & president
These 15 states have the most physicians
Data breaches fall 17 percent in August — Which healthcare provider was hit the worst?
